Moderna, Inc. — Director's Dealing 2022

Jun 29, 2022

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2022-06-28

Reporting Person: Garay Arpa (Chief Commercial Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$137.15	2032-06-05	Common Stock (34766)		Direct
Restricted Stock Units	$0		Common Stock (18248)		Direct

Footnotes

F1: 25% of this option will vest and become exercisable on June 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

F2: 25% of the shares subject to this restricted stock unit award will vest on June 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.